These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28858443)

  • 41. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K; Andersen HF; Reines EH
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic subgroups for citalopram response in the STAR*D trial.
    Jakubovski E; Bloch MH
    J Clin Psychiatry; 2014 Jul; 75(7):738-47. PubMed ID: 24912106
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impaired insight into delusions predicts treatment outcome during a randomized controlled trial for Psychotic Depression (STOP-PD study).
    Gerretsen P; Flint AJ; Whyte EM; Rothschild AJ; Meyers BS; Mulsant BH
    J Clin Psychiatry; 2015 Apr; 76(4):427-33. PubMed ID: 25919834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sex differences in response to citalopram: a STAR*D report.
    Young EA; Kornstein SG; Marcus SM; Harvey AT; Warden D; Wisniewski SR; Balasubramani GK; Fava M; Trivedi MH; John Rush A
    J Psychiatr Res; 2009 Feb; 43(5):503-11. PubMed ID: 18752809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life.
    Zimmerman M; Ruggero CJ; Chelminski I; Young D; Posternak MA; Friedman M; Boerescu D; Attiullah N
    J Clin Psychiatry; 2006 Oct; 67(10):1536-41. PubMed ID: 17107244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission?
    Zimmerman M; Martinez JA; Attiullah N; Friedman M; Toba C; Boerescu DA; Rahgeb M
    J Clin Psychiatry; 2012 Jun; 73(6):790-5. PubMed ID: 22569085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Health-related quality of life assessment in depression after low-frequency transcranial magnetic stimulation].
    Dumas R; Boyer L; Richieri R; Guedj E; Auquier P; Lançon C
    Encephale; 2014 Feb; 40(1):74-80. PubMed ID: 24091070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study.
    Perlis RH; Fraguas R; Fava M; Trivedi MH; Luther JF; Wisniewski SR; Rush AJ
    J Clin Psychiatry; 2005 Feb; 66(2):159-66; quiz 147, 273-4. PubMed ID: 15705000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study.
    DiBernardo A; Lin X; Zhang Q; Xiang J; Lu L; Jamieson C; Benson C; Lee K; Bodén R; Brandt L; Brenner P; Reutfors J; Li G
    BMC Psychiatry; 2018 Oct; 18(1):352. PubMed ID: 30373547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
    Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
    BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
    Brown ES; Vigil L; Khan DA; Liggin JD; Carmody TJ; Rush AJ
    Biol Psychiatry; 2005 Dec; 58(11):865-70. PubMed ID: 15993860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.
    Amsterdam JD; Wang CH; Shwarz M; Shults J
    J Affect Disord; 2009 Jan; 112(1-3):219-30. PubMed ID: 18486235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis.
    Ulbricht CM; Dumenci L; Rothschild AJ; Lapane KL
    Am J Mens Health; 2018 Jan; 12(1):5-13. PubMed ID: 26438468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
    Uher R; Perlis RH; Henigsberg N; Zobel A; Rietschel M; Mors O; Hauser J; Dernovsek MZ; Souery D; Bajs M; Maier W; Aitchison KJ; Farmer A; McGuffin P
    Psychol Med; 2012 May; 42(5):967-80. PubMed ID: 21929846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
    Rush AJ; Wisniewski SR; Zisook S; Fava M; Sung SC; Haley CL; Chan HN; Gilmer WS; Warden D; Nierenberg AA; Balasubramani GK; Gaynes BN; Trivedi MH; Hollon SD
    Psychol Med; 2012 Jun; 42(6):1131-49. PubMed ID: 22008447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
    Rapoport MJ; Mitchell RA; McCullagh S; Herrmann N; Chan F; Kiss A; Feinstein A; Lanctôt KL
    J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
    Warden D; Rush AJ; Wisniewski SR; Lesser IM; Kornstein SG; Balasubramani GK; Thase ME; Preskorn SH; Nierenberg AA; Young EA; Shores-Wilson K; Trivedi MH
    Int J Neuropsychopharmacol; 2009 May; 12(4):459-73. PubMed ID: 18611293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.
    Jha MK; South C; Trivedi J; Minhajuddin A; Rush AJ; Trivedi MH
    Int J Neuropsychopharmacol; 2019 May; 22(5):339-348. PubMed ID: 30958879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.